IQVIA Holdings, Inc. · NYSE:IQV

IQVIA — Investor Presentation (November 2021)

31 slides from IQVIA's investor presentation, Nov 4, 2021

  1. Slide 1: US Cough, Cold and Flu 2021/22 - Navigating the Unknown

    US Cough, Cold and Flu 2021/22 - Navigating the Unknown November 4th 2021 © 2021. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.

  2. Slide 2: Speakers

    Speakers Doug Long Chip Schaible Matt Stewart Vice President Director, Business Development, Marketing Manager, Global, of Industry Relations US Consumer Health, IQVIA Consumer Health IQVIA IQVIA Consumer Health US Cough, Cold and Flu 2021/22 - Navigating the Unknown 2

  3. Slide 3: Cough/Cold/Flu Global Sales Snapshot

    Cough/Cold/Flu Global Sales Snapshot 3

  4. Slide 4: CCR sales hit by Covid-19 restrictions and consumer stockpiling

    CCR sales hit by Covid-19 restrictions and consumer Global stockpiling By contrast preventative products – VMS – benefitted from growing consumer interest in ‘wellness’ Global OTC – Core Categories MAT Q2 2021 Value Growth (%) Value Share (%) Global OTC 2.1% Other OTC 20.0% VMS 21.3% VMS 10.7% CCR -

  5. Slide 5: CCR rebounded in Q2 year-on-year from low base

    Global CCR rebounded in Q2 year-on-year from low base Trend towards prevention/wellness maintaining its momentum Global OTC – Core Categories Q2 2021 vs Q2 2020 Value Growth (%) Value Share Q2 2021 (%) Global OTC 14.6% Other OTC 20.2% VMS 20.6% VMS 10.2% CCR 28.7% Skin 9.3% Pain Relief 17.5% CCR 18.

  6. Slide 6: US Update - COVID Cases, Deaths and Vaccines

    US Update - COVID Cases, Deaths and Vaccines 6

  7. Slide 7: US COVID-19 cases and deaths are decreasing

    100,000 150,000 200,000 250,000 300,000 350,000 0 50,000 1/23/20 2/23/20 3/23/20 4/23/20 5/23/20 6/23/20 US Cough, Cold and Flu 2021/22 - Navigating the Unknown 7/23/20 Cases 8/23/20 9/23/20 10/23/20 11/23/20 Averages 12/23/20 1/23/21 2/23/21 3/23/21 7-Day Moving Avg 4/23/21 5/23/21 U.S. COVID Cases

  8. Slide 8: Daily US COVID-19 cases falling from late-August summer peak

    Daily US COVID-19 cases falling from late-August summer peak The amount of daily tests coming back positive is also declining U.S. COVID Daily Cases 350,000 300,000 250,000 200,000 150,000 100,000 50,000 0 10/22/20 11/12/20 12/24/20 10/14/21 3/5/20 7/9/20 2/4/21 4/8/21 7/1/21 9/2/21 5/7/20 1/23/20 2

  9. Slide 9: Daily US COVID-19 deaths have been decreasing in recent weeks

    Daily US COVID-19 deaths have been decreasing in recent weeks U.S. COVID Daily Deaths 4,500 4,000 3,500 3,000 2,500 2,000 1,500 1,000 500 0 3/5/20 5/7/20 7/9/20 10/22/20 4/8/21 7/1/21 11/12/20 12/24/20 2/4/21 9/2/21 10/14/21 1/23/20 2/13/20 3/26/20 4/16/20 5/28/20 6/18/20 7/30/20 8/20/20 9/10/20 10/

  10. Slide 10: Percentage of cases, deaths, and US population by age group

    Percentage of cases, deaths, and US population by age group 35 30 28.9 26.5 25 21.9 21.9 19.3 20 19.2 16.4 16.6 16.7 Percentage of deaths 14.5 Percent of cases 15 13.5 12.3 Percent of US population 9.6 10 8.7 7.1 6 5.4 5.1 4.9 5 4.3 3.7 3.6 2.5 2.7 2.5 1.6 2 2 0.7 0 0 0 0 0 0-4 Years 5-11 Years 12-1

  11. Slide 11: Percentage of cases, deaths, and US population by ethnicity

    Percentage of cases, deaths, and US population by ethnicity 70 59.5 60.11 60 52.3 50 40 Percent of deaths 30 26.2 Percent of cases Percent of US population 20 17.9 18.45 13.9 11.8 12.54 10 5.76 5.3 1.1 3.5 3 0.3 3.8 1.1 2.22 0.74 0.2 0.182 0 Hispanic/Latino American Indian / Asian Non- Black Non- Na

  12. Slide 12: COVID-19 vaccination rates have been levelling off

    COVID-19 vaccination rates have been levelling off… As of October 11, 7-day average of daily doses administered is approximately 556,000 Daily Count of Total Doses Administered and Reported to CDC by Date Administered, United States​​ 5000000 4500000 4000000 3500000 3000000 2500000 2000000 Total Dos

  13. Slide 13: Retail COVID-19 vaccines increased in October due to boosters

    Millions 1 2 3 4 5 6 7 8 0 12/18/20 12/25/20 01/01/21 01/08/21 01/15/21 01/22/21 US Cough, Cold and Flu 2021/22 - Navigating the Unknown 01/29/21 02/05/21 02/12/21 02/19/21 02/26/21 03/05/21 Chain 03/12/21 03/19/21 03/26/21 04/02/21 04/09/21 04/16/21 Independents 04/23/21 04/30/21 05/07/21 05/14/21

  14. Slide 14: 57.5% of the entire US population is fully vaccinated

    57.5% of the entire US population is fully vaccinated; Booster doses not available for first category VACCINES VACCINES VACCINES VACCINES ADMINISTERED ≥ 12 ADMINISTERED ≥ 18 ADMINISTERED ≥ 65 ADMINISTERED 77.7% 66.5% 79.6% 96.5% 65.8% 57.5% 84.7% 69.0% 220.6 220.4 205.5 190.8 52.8 190.7 178.2 46.3 3

  15. Slide 15: Current season closely following the 2019-2020 flu vaccination trendline

    So far, the current season is closely following the 2019-2020 Flu vaccination trendline Total Retail Flu Vaccinations Season to Date Vaccinations 6 35 33.3 5 30 4 25 20.7 20.7 20 Millions Millions 3 15 2 10 1 5 - - 8/6/21 9/3/21 1/7/22 2/4/22 3/4/22 10/15/21 10/29/21 11/12/21 11/26/21 12/10/21 12/24

  16. Slide 16: Flu season in Australia as an early indicator of the US season

    The Flu season in Australia can be an early indicator of our season in the US and current trends are showing a weak season 72.8% of Australians 18-64 have received a flu vaccine, compared to 82% at the same time last year 90.7% of Australians 65+ have received a flu vaccine, compared to 93.9% at the

  17. Slide 17: US Cough, Cold and Flu 22/22 – Into the Unknown

    US Cough, Cold and Flu 22/22 – Into the Unknown 17

  18. Slide 18: FAN and AAN

    FAN and AAN Align suppliers and retailers to seasonal consumer suffering driven by Cough-Cold, ILI & Allergies FAN & AAN reporting uses real-time Suppliers/Retailers data from IQVIA’s longitudinal patient-level data warehouser Timed Media & Market Level Promotions • IQVIA patient-level data is the b

  19. Slide 19: A lot of firsts because of COVID going into the 21/22 season

    A lot of firsts because of COVID going into the 21/22 season More unknowns than during the 20/21 season as pandemic-driven cultural changes kick in Adults Peds All • Working from home • Masking in schools (Varies by • Increased use of prevention • Companies telling employees stated and county) type

  20. Slide 20: As restrictions eased reported cough, cold, flu symptoms shot up

    As restrictions eased reported cough, cold, flu symptoms shot up FAN report for all symptoms indicates more cases beginning in May in comparison to the past 2yrs FAN Report: All Symptoms 45 40 35 30 Millions 25 20 15 10 5 0 1/2/21 5/8/21 6/5/21 7/3/21 10/10/20 10/24/20 11/21/20 12/19/20 8/15/20 8/29

  21. Slide 21: Affected Population above previous seasons and +46% on 2020

    Now total affected pop. is above previous seasons and +46% on 2020 Historically, not seen these levels of affected pop. in late Sept/early Oct since 2015/2016 FAN Total Affected Population 2015/16 through 2021/22 43,000,000 38,000,000 33,000,000 Affected Population 28,000,000 18.8m 19.0m 18.5m 18.3m

  22. Slide 22: Cough, Earache, Nasal, Fever and Sore Throat running ahead of seasonal norms

    Millions Millions 10 20 30 40 0 0.5 1.5 2.5 0 1 2 8/15/20 8/15/20 9/15/20 9/15/20 10/15/20 10/15/20 11/15/20 11/15/20 12/15/20 12/15/20 1/15/21 1/15/21 Cough 2/15/21 2/15/21 Earache US Cough, Cold and Flu 2021/22 - Navigating the Unknown 3/15/21 3/15/21 4/15/21 4/15/21 5/15/21 5/15/21 6/15/21 6/15/2

  23. Slide 23: Yet season on track to be well below historic rates – why?

    Yet season on track to be well below historic rates – why? Q1 2022 offering biggest opportunity in terms of year-on-year uplift 58 • The total affected population will 53 trend over 2020. 48 • The biggest opportunity overall will 43 be in Q1 for both adult & pediatric segment. 38 Millions 33 28 23 1

  24. Slide 24: While pediatric segment should be positive across the season

    While pediatric segment should be positive across the season… For Q3 2021, the affected pediatric population is +116.5% vs. Q3 2020. 22,000,000 • The pediatric segment provides the 20,000,000 biggest opportunity over a year ago, 18,000,000 as this segment is closer to being back to ‘normal’ than the

  25. Slide 25: Risk that the Adult segment will flatten damaging sales

    There is a risk that the Adult segment will flatten damaging sales For Q3 2021, the Affected Population is +25.7% vs. Q3 2020…the adult segment potentially has a risk in the back half of Q4 40,000,000 • The adult segment should see some softening in Q4 Vs. YAG, because it 35,000,000 is up against CO

  26. Slide 26: Opportunity lies in Q1/22 due to big drop in Q1/21 affected pop.

    Opportunity lies in Q1/22 due to big drop in Q1/21 affected pop. Q1 2021 down -45.6% in Avg. Weekly AP as markets remained closed and vaccines rolled out. Average weekly affected 40,000,000 population 2010-2021 35,064,828 35,356,354 34,582,184 35,000,000 30,004,447 31,179,611 31,610,275 31,046,147 3

  27. Slide 27: Conclusion– Opportunities and Challenges

    Conclusion– Opportunities and Challenges 27

  28. Slide 28: Seasons will weaken generally, but adaptation can equal success

    Seasons will weaken generally, but adaptation can equal success Season’s tail is getting stronger and opportunity to be more targeted Opportunities Challenges Look later in the Illness Levels Prevention is The best is behind season Target hot spots where working us Tail of the season is getting affe

  29. Slide 29: Q&A

    SIQVIA CONSUMER HEALTH Q&A 29

  30. Slide 30: Your IQVIA Consumer Health contact

    Your IQVIA Consumer Health contact Chip Schaible Director, Business Development, US Consumer Health, IQVIA Consumer Health Please submit your questions and enquiries to: consumer.health@iqvia.com Or visit www.iqviaconsumerhealth.com for more information US Cough, Cold and Flu 2021/22 - Navigating th

  31. Slide 31: Thank you

    SIQVIA CONSUMER HEALTH Thank you

Iqvia — Investor Presentation (November 2021) on 6ix